Effect of RAS and BRAF mutations on peritoneal metastasis risk and cytoreductive surgery/hyperthermic intraperitoneal chemotherapy efficacy in colorectal cancer: A systematic review and meta-analysis.
Ziming GaoXiang QiRuiying WangZhitong WenHao QiMingguang JuXiaoxu LiuJunye WangHeng ZhouZhi ZhuXiaofang LiuKai LiPublished in: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2024)
BRAF mutation, rather than RAS mutation, was a high-risk factor for CRC-PM. And both BRAF and RAS mutations negatively affected the prognosis of CRS/HIPEC in CRC-PM patients. Our results could provide suggestions for the selection of comprehensive treatment for CRC-PM with RAS/BRAF mutations.
Keyphrases
- wild type
- particulate matter
- air pollution
- end stage renal disease
- polycyclic aromatic hydrocarbons
- heavy metals
- ejection fraction
- metastatic colorectal cancer
- chronic kidney disease
- minimally invasive
- water soluble
- prognostic factors
- patient reported outcomes
- acute coronary syndrome
- combination therapy
- smoking cessation